To view this notification widget you need to have JavaScript enabled. This notification widget was easily created with NotifySnack.
Deep Vein Thrombosis
  Loading... Please wait...


Our Newsletter

Deep Vein Thrombosis

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Results may vary.  Copyright © 2004 Biomedic Labs. All rights reserved Terms & Conditions

 Introduction to Deep Vein Thrombosis (DVT)

Arteries have thin muscles within their walls to be able to withstand the pressure of the heart pumping blood to the far reaches of the body. Veins don't have a significant muscle lining, and there is nothing pumping blood back to the heart except physiology. Blood returns to the heart because the body's large muscles squeeze the veins as they contract in their normal activity of moving the body. The normal activities of moving the body returns the blood back to the heart.

There are two types of veins in the leg; superficial veins and deep veins. Superficial veins lie just below the skin and are easily seen on the surface. Deep veins, as their name implies, are located deep within the muscles of the leg. Blood flows from the superficial veins into the deep venous system through small perforator veins. Superficial and perforator veins have one-way valves within them that allow blood to flow only in the direction of the heart when the veins are squeezed.

A blood clot (thrombus) in the deep venous system of the leg is not dangerous in itself. The situation becomes life-threatening when a piece of the blood clot breaks off (embolus, pleural=emboli), travels downstream through the heart into the pulmonary circulation system, and becomes lodged in the lung. Diagnosis and treatment of a deep venous thrombosis (DVT) is meant to prevent pulmonary embolism.

Clots in the superficial veins do not pose a danger of causing pulmonary emboli because the perforator vein valves act as a sieve to prevent clots from entering the deep venous system. They are usually not at risk of causing pulmonary embolism.

Serracor-NK and Deep Vein Thrombosis

Serracor-NK a systemic enzyme formulation containing two enterically coated systemic enzymes serrapeptase and nattokinase. Serrapeptase clinically proven to dissolve fibrin through out the blood stream and within non living tissue within the body. Nattokinase is clinically proven to break down blood clots, improve circulation and cleanse the veins and arteries. People suffering from Deep Vein Thrombosis ( DVT ) and Pulmonary Embolism will benefit from the use of Serracor-NK. When applying serrapeptase and nattokinase to your bodies blood, you are taking a multi enzymatic approach to the break down and dissolvment of the blood clots and fibrin be built up along your veins and arteries. The benefits of these two enzymes goes well beyond their use for the disformation of blood clotting. Nattokinase is a highly recomended enzyme in Japan for over 20 years and its use's for anti-coagulation has climb dramatically in the past 10 years as more clinical research has been conducted on its use anti-thrombotic conditions. Serrapeptase is the number 1 ingreident in all systemic formulas for the break down of fibrin (scar tissue). Fibrin is a protein marcophage that is formed when trauma or inflammation occurs in the body. Your bodies reaction to this fibrin thrombosis is a immune response that is ineffective and will result in higher fibrin levels in the blood.

Serracor-NK is a effective alternative to DVT surgery and depending on the length of this condition users of Serracor-NK could make signifigant strides against DVT in a matter of months. People looking to add Serracor-NK to their supplemental regament should also consider adding Serra RX80, a enterically coated serrapeptase product that when coupled with Serracor-NK puts people suffering from DVT in the best scencario to stop the formation of blood clots, thrombosis and the dissolvement of fibrin formations in the veins and arteries. Below we provide a suggested use dosage chart for users of both products.


Deep Vein Thrombosis Dosage Chart

Introduction Phase  7 days period  (not needed for exsisting serracor users)                       
SERRACOR-NK-2 Capsules a day for 3 days   
SERRA RX80-1 Capsule a day for 3 days

Therapeutic Phase  30 days or until desiredresults (30-270 days)
SERRACOR-NK-3 Capsules, 3x a day

SERRA RX80-1 Capsules, 3x a day

Maintenance Phase  30-360 days (depending upon each person)

SERRACOR-NK-1 Capsule, 3x a day
SERRA RX80-1 Capsule, 2x a day


To view the clinical studies on Nattokinase and Serrapeptase please use the links below:

Nattokinase clinical on Anti-Thrombotic effects

Nattokinase clinical #2

Nattokinase clinical #3

Serrapeptase Clinicals

 If you have questions and would like to speak with a product specialist please call 1-888-298-7363.

To read more about Serracor-NK and to the visit the product information page please click here.